Biotech startups can extend their financial runway by aligning cash planning with scientific milestones rather than simply budgeting by calendar months. This approach involves creating milestone-based budgets, forecasting cash burn under multiple scenarios, managing contract research expenses, pursuing non-dilutive funding such as government grants and R&D tax credits, and preparing for the next fundraising round well before cash reserves become critically low. fractional CFO for biotech companies
In most industries, running low on cash creates operational difficulties. In biotechnology, it can threaten an entire research program that has taken years to develop. A promising compound, innovative platform technology, or diagnostic product can lose momentum if funding runs out just months before the results needed to secure the next investment round become available.
Research timelines can change unexpectedly. Experiments may need to be repeated, clinical studies can take longer than expected, and regulatory requirements can introduce additional costs. Meanwhile, salaries, laboratory expenses, and research commitments continue to consume cash.
That is why many life science founders consider fractional CFO services for biotech companies before they have the resources to hire a full-time finance executive. The objective is to make every dollar of available capital support meaningful scientific progress while preserving enough flexibility to manage unexpected challenges.
This guide explores practical cash planning strategies that help biotech startups extend their runway, manage financial uncertainty, and prepare for future funding opportunities.
Why Cash Planning Is Different for Biotech Startups
A software business may be able to reduce marketing expenses, adjust pricing, or generate additional revenue relatively quickly. Early-stage biotech companies generally have fewer immediate options. They often operate without significant revenue while investing heavily in research, development, testing, and regulatory preparation.
Several factors make financial planning particularly challenging for biotech companies.
Binary research outcomes: A single study result can significantly affect a company’s valuation, development strategy, and ability to attract investors.
Irregular spending patterns: Contract research organization (CRO) payments, manufacturing activities, and clinical trial expenses can create substantial cash outflows at specific points in a project.
Long lead times: Laboratory materials, specialized equipment, and external research services may require months of advance planning.
Milestone-dependent fundraising: Investors typically want evidence of scientific progress, safety, efficacy, or regulatory readiness before committing additional capital.
Specialized personnel: Experienced scientists and technical professionals are expensive to recruit and difficult to replace. Reducing headcount can also slow research progress.
Because of these challenges, a traditional annual budget is rarely sufficient. Biotech startups need financial models that connect spending decisions directly to scientific milestones and future financing requirements.
Build a Budget Around Scientific Milestones
A milestone-based budget organizes expenses around specific scientific, clinical, or regulatory achievements rather than relying exclusively on departmental spending categories.
Examples include completing investigational new drug (IND)-enabling studies, generating proof-of-concept data, completing preclinical research, or reaching a first-in-human clinical trial milestone.
The key question is straightforward: How much capital is required to reach the next milestone that could improve the company’s financing prospects?
Start by identifying the milestones that will support the next fundraising round. Define the evidence, data, or approvals investors are likely to expect.
Next, map the activities required to achieve each milestone. Include laboratory studies, materials, manufacturing, external research services, regulatory work, staffing, and related expenses.
Estimate the cost and timing of each activity with input from scientific leadership and vendors. Include realistic contingency reserves because experiments may require repetition and research timelines can change.
Finally, distinguish essential spending from activities that can be delayed without compromising critical scientific objectives.
This approach gives founders and board members a clearer understanding of how financial resources translate into scientific progress. Instead of reviewing expenses in isolation, leadership can evaluate whether current spending is sufficient to achieve the next value-creating milestone.
Forecast Cash Burn Under Multiple Scenarios
A single financial forecast can create a misleading impression of certainty. Biotech startups should model several possible outcomes to understand how delays, spending changes, and unexpected funding affect their financial position.
Base-case scenario: Assumes milestones are achieved according to the current schedule and budget. It supports regular operational planning and investor updates.
Delay scenario: Assumes important studies or regulatory activities take three to six months longer than expected. It tests whether the company can withstand realistic setbacks.
Lean scenario: Assumes selected non-essential programs are paused, hiring is frozen, and discretionary expenses are reduced. It shows how far existing cash can stretch under pressure.
Upside scenario: Assumes favorable data, an early partnership, or grant funding becomes available sooner than anticipated. It helps leadership evaluate opportunities to accelerate research.
Every scenario should show monthly cash balances, projected burn rates, expected funding inflows, and the date cash may fall below a defined minimum threshold.
Monthly rolling forecasts are particularly useful because they incorporate actual financial results instead of relying on assumptions made several months earlier. This allows leadership to identify problems sooner and adjust spending before available options become limited.
Experienced cash flow management consulting professionals can help establish these forecasting processes and provide management with a consistent view of the company’s financial position.
Control the Largest Cost Drivers
A relatively small number of expense categories often account for most of a biotech startup’s cash burn. Managing these costs carefully can preserve capital without unnecessarily slowing scientific development.
Contract Research and Manufacturing
CROs and contract manufacturers can represent a substantial portion of total expenditure. Review contracts for payment schedules, cancellation provisions, change-order terms, and additional fees.
Where practical, structure payments around completed deliverables and track work performed against amounts paid. This reduces the risk of paying substantially ahead of project progress.
Headcount and Specialized Expertise
Scientific salaries and benefits can consume a significant share of available capital. Founders should evaluate whether certain specialized activities can temporarily be handled by consultants or contract scientists.
However, staffing decisions should consider scientific continuity, intellectual property protection, regulatory requirements, and the risk of delaying critical experiments.
Laboratory Space and Equipment
Shared laboratory facilities, incubators, and equipment leasing can reduce upfront commitments. Purchasing expensive equipment before it becomes essential may tie up capital that could otherwise support research.
Compare the total costs of leasing, sharing, and purchasing before making major commitments.
Materials and Research Supplies
Reagents, specialty chemicals, cell lines, and other research materials can involve high costs and long delivery times. Coordinated purchasing helps prevent emergency orders, unnecessary inventory, and material waste.
Research Accruals
Research expenses frequently arise before the corresponding invoices arrive. Accurate monthly accruals ensure that financial statements reflect work already performed.
Without proper accrual accounting, a company may underestimate its expenses and overestimate its remaining runway. Reliable financial reporting is therefore essential for sound cash management.
Layer In Non-Dilutive Funding
Non-dilutive funding can extend a biotech startup’s runway without requiring the company to issue additional equity. The availability and suitability of each option depend on the company’s stage, research program, eligibility, and funding terms.
Government Grants
Programs such as Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR), along with grants from the National Institutes of Health and other agencies, can support eligible research activities.
These programs often involve application deadlines, reporting requirements, and restrictions on how funds may be used. Strong accounting controls help companies manage grant-funded projects appropriately.
R&D Tax Credits
Research into compounds, therapies, diagnostics, and platform technologies may qualify for applicable research tax credits.
Working with an experienced R&D tax credit consulting provider can help identify potentially qualifying employee wages, research supplies, and eligible contract research expenses.
Certain qualified small businesses may be able to elect to apply eligible federal research credits against payroll taxes, subject to statutory requirements and applicable limits. Companies should also evaluate how grant funding and other reimbursements affect qualifying research expenses.
Strategic Partnerships
Licensing arrangements, research collaborations, and co-development agreements can generate upfront payments, milestone fees, or shared research funding.
These partnerships may also provide access to specialized capabilities and external validation. Founders should evaluate the financial benefits alongside intellectual property rights, exclusivity provisions, and long-term commercial implications.
Venture Debt
Venture debt may provide additional capital to companies with suitable investor backing and financing prospects. However, debt introduces repayment obligations, interest costs, and potentially restrictive covenants.
Before accepting venture debt, leadership should model repayment scenarios and assess whether the financing will genuinely support the company through its next major milestone.
Protect the Cash You Already Have
Extending runway is not only about reducing spending. It also requires disciplined management of existing cash reserves.
Establish a minimum cash threshold that triggers specific actions, such as beginning a fundraising process or activating the lean operating plan.
Review banking relationships and deposit concentration to understand liquidity and institutional exposure. Keep funds accessible for upcoming operating commitments.
Invest idle cash conservatively, using liquid options that align with the company’s investment policy and risk tolerance.
Create approval limits for major expenses so that significant commitments receive appropriate financial and operational review.
Finally, provide the board with regular cash reports that compare actual results with the approved budget. Consistent reporting helps directors identify risks and support timely decisions.
Start the Next Fundraising Round Early
One of the most damaging financial planning mistakes in biotech is waiting until cash reserves become critically low before approaching investors.
Fundraising can take six months or longer, depending on market conditions, scientific progress, investor interest, and the complexity of the transaction. Companies that approach investors with limited runway may have fewer financing options and less negotiating leverage.
Founders should begin preparing well before reaching their minimum cash threshold. The plan should allow sufficient time to achieve the next milestone and accommodate a slower-than-expected financing process.
Preparation typically includes updating the financial model, organizing the data room, reconciling research accruals, reviewing capitalization table records, and developing a clear use-of-funds plan.
The financial model should explain how the proposed investment will support specific research activities, when major milestones are expected, and what additional capital may be required afterward.
A well-prepared fundraising strategy helps investors understand how their capital will translate into measurable progress.
How K-38 Consulting Supports Biotech Financial Planning
K-38 Consulting is a Raleigh, North Carolina-based finance firm founded by Dallas Alford IV, CPA. The firm provides CFO support to startups and midsize businesses, including companies that need more sophisticated financial planning as they develop and pursue additional funding.
Its service model typically pairs clients with a finance team that includes a controller and a CFO. The controller focuses on accounting accuracy, research accruals, and dependable monthly financial reporting. The CFO concentrates on cash runway, milestone-based budgeting, scenario forecasting, funding strategy, and fundraising preparation.
For biotech founders, this combination can help connect scientific priorities with financial decisions while allowing research teams to focus on their core work.
K-38 Consulting also offers R&D tax credit services, enabling eligible clients to evaluate potential tax-credit opportunities as part of their broader cash planning strategy. The firm works with accounting platforms such as QuickBooks and NetSuite and uses web-based forecasting tools to help leadership monitor burn rates and cash balances.
According to the firm, many businesses spend 10 to 15 hours per month on manual accounting tasks, making automation an important part of its finance operations approach.
The company also cites Dover Therapeutics, a biotech startup, as a client that benefited from support with financial operations, cash flow, business processes, and forecasting tools. These reported outcomes illustrate the potential role of financial expertise in supporting biotech decision-making.
K-38 Consulting serves businesses in locations including Raleigh, Charlotte, Atlanta, Tampa, Miami, Austin, New York City, Chicago, San Francisco, San Jose, and Los Angeles.
Biotech founders considering additional financial support can explore a strategy session with the firm to review runway assumptions, upcoming milestones, funding plans, and financial readiness for the next financing round.
Runway Stress Test: Eight Questions for Your Leadership Team
Use these questions to evaluate whether your current financial plan is strong enough to support continued research.
Do we know exactly how much cash is required to reach the next value-creating milestone?
Does our forecast include a realistic delay scenario, and can we survive it?
Are research accruals recorded accurately every month?
Are CRO and manufacturing payments connected to measurable deliverables?
Have we reviewed our eligibility for R&D tax credits and any applicable payroll tax offset?
Are we pursuing grants and strategic partnerships that fit our research programs?
Do we have a defined minimum cash threshold and a practical lean operating plan?
When must fundraising begin to provide sufficient time for closing before cash becomes critically low?
If any answer is uncertain, prioritize that issue in the next financial review.
Frequently Asked Questions (FAQ)1. How can a biotech startup extend its cash runway?
A biotech startup can extend its runway by aligning spending with scientific milestones, improving cash forecasts, controlling major research expenses, pursuing eligible non-dilutive funding, and preparing early for future fundraising.
2. How much runway should a biotech startup have after raising capital?
The appropriate runway depends on the research program, expected milestone dates, development costs, and fundraising environment. Companies should raise enough capital to reach their next major value-creating milestone while maintaining a reasonable contingency buffer for delays.
3. Why is milestone-based budgeting important for biotech companies?
Milestone-based budgeting connects financial resources to specific scientific, clinical, or regulatory achievements. It helps founders determine how much capital is needed to produce meaningful results and prepare for the next financing round.
4. What is cash burn in a biotech startup?
Cash burn is the amount of cash a company consumes over a given period to operate and develop its products. Net cash burn generally accounts for operating cash inflows as well as outflows, while gross cash burn focuses on cash spending before those inflows.
5. Why are research accruals important for cash planning?
Research accruals record expenses when the underlying work is performed, even if invoices have not yet arrived. Accurate accruals provide a more realistic picture of expenses, financial performance, and remaining runway.
6. Can a pre-revenue biotech startup claim R&D tax credits?
Potentially. Eligible businesses may qualify for applicable research tax credits even before generating revenue. Certain qualified small businesses may also elect to apply a portion of eligible federal research credits against payroll taxes, subject to applicable rules and limitations. Professional tax advice can help determine eligibility.
7. What types of non-dilutive funding are available to biotech startups?
Potential options include government research grants, qualifying R&D tax credits, strategic research partnerships, licensing payments, and certain collaborative funding arrangements. Each option has its own eligibility criteria, obligations, and limitations.
8. How can biotech startups reduce CRO and manufacturing expenses?
Startups can review vendor contracts, negotiate milestone-based payment schedules, monitor change orders, compare qualified providers, and track deliverables against payments. Cost reductions should not compromise research quality or regulatory compliance.
9. When should a biotech startup hire a fractional CFO?
A biotech startup may benefit from fractional CFO support when preparing for a funding round, planning expensive preclinical or clinical activities, managing grant funding, improving financial reporting, or building reliable cash forecasts. The right timing depends on the company’s complexity and available internal expertise.
10. How early should biotech companies begin fundraising?
Fundraising should begin early enough to accommodate investor due diligence, negotiations, documentation, and possible delays. Because some fundraising processes take six months or longer, companies should work backward from their expected cash threshold and next milestone rather than waiting until reserves are low.
11. Is venture debt a good way to extend biotech runway?
Venture debt can provide additional capital in suitable circumstances, but it introduces repayment obligations and other contractual risks. Companies should evaluate repayment capacity, financing costs, covenants, and the expected timing of future milestones before proceeding.
12. How can a CFO help a biotech startup prepare for investors?
A CFO can help build financial models, prepare milestone budgets, validate burn-rate assumptions, organize financial records, evaluate funding needs, and explain how new investment will support measurable progress. This can improve financial transparency and help leadership communicate a credible financing plan.
Conclusion: Buying Time for Scientific Progress
In biotechnology, time can be one of a company’s most valuable resources, and cash is what allows scientific work to continue.
Founders who build budgets around milestones, forecast multiple scenarios, manage major expenses, maintain accurate research accruals, and pursue suitable non-dilutive funding can improve their chances of reaching the next critical stage of development.
Preparing for fundraising before cash becomes scarce is equally important. A disciplined approach gives leadership more flexibility to respond to setbacks, negotiate with investors, and protect promising research programs.
With an experienced finance partner such as K-38 Consulting, biotech companies can strengthen their financial planning, gain better visibility into their runway, and keep capital allocation aligned with the scientific breakthroughs they aim to deliver.